

## **REMARKS**

Claims 1 to 145, as amended, appear in this application for the Examiner's review and consideration. The claims have been renumbered to correct for the typographic error that included a second claim 113. Claims 13 to 145 are withdrawn from prosecution, as being directed to a non-elected invention. The amendments are fully supported by the specification and claims as originally filed. Therefore, there is no issue of new matter.

For the reasons set forth on page 2 of the Office Action, restriction was required under 35 U.S.C. § 121 to one of:

- I. Claims 1-12, drawn to a method of modifying the bioavailability of a bioactive substance;
- II. Claims 13-15, drawn to a method of modifying the production of nitric oxide in a mammal;
- III. Claim 16, drawn to a method for increasing homogeneity and flattening of a bioactive substance;
- IV. Claims 17-21, drawn to a method of reducing blood levels of homocysteine;
- V. Claims 22-26, drawn to a method for treating anxiety;
- VI. Claims 27-31, drawn to a method for treating depression;
- VII. Claims 32-36, drawn to a method for treating obsessive compulsive symptoms;
- VIII. Claims 37-41, drawn to a method for treating paranoia;
- IX. Claims 42-46, drawn to a method for treating hostility;
- X. Claims 47-51, drawn to a method of treating perceptions of bodily distress;
- XI. Claims 52-56, drawn to a method of increasing systemic DNA methylation and SAME levels;
- XII. Claims 57-59, drawn to a method for treating autoimmune disorders;
- XIII. Claims 60-64, drawn to a method for treating elevated serum total cholesterol levels;
- XIV. Claims 65-69, drawn to a method for treating elevated serum LDL cholesterol levels;
- XV. Claims 70-74, drawn to a method for treating elevated serum total-to-HDL cholesterol levels;
- XVI. Claims 75-79, drawn to a method for treating elevated systolic blood pressure;
- XVII. Claims 80-84, drawn to a method for treating elevated diastolic blood pressure;
- XVIII. Claims 85-89, drawn to a method for treating erectile dysfunction;

XIX. Claims 90 and 91, drawn to a method for improving immunologic function;

XX. Claims 92 and 93, drawn to a method for modifying amino acids to reduce immune reaction;

XXI. Claims 94 and 95, drawn to a method for modifying amino acids to reduce inflammation;

XXII. Claims 96-98, drawn to a method of increasing the voltage potential of the brain;

XXIII. Claims 99-101, drawn to a method for improving the coherence of brain wave patterns;

XXIV. Claims 102 and 103, drawn to a method for improving the quality of crystal formation;

XXV. Claims 104 and 105, drawn to a method for improving the quality of crystals;

XXVI. Claims 106 and 107, drawn to a method for generating highly crystalline and homogeneous simvastatin;

XXVII. Claims 108 and 109, drawn to a method for generating amorphous simvastatin;

XXVIII. Claims 110 and 111, drawn to a method for improving immunologic function;

XXIX. Claims 112, and 113, drawn to a method for improving immunologic function;

XXXVI. Claims 128 and 129, drawn to a method for increasing the bioavailability of high energy phosphates of nucleotides or deoxynucleotides;

XXXVII. Claim 130, drawn to a method for increasing the bioavailability of nucleic acid bases, nucleosides or deoxynucleosides, or nucleotides or deoxynucleotide monophosphates, diphosphates, or triphosphates;

XXXVIII. Claim 131, drawn to a method of amplifying or modifying the production or purification of a selected stereoisomer or epimer of a bioactive substance;

XXXIX. Claims 132-134, drawn to a method of reshaping prions or other pathogenic proteins to reduce their pathogenicity;

XL. Claims 135-137, drawn to a method of reshaping pathogenic substances or components of infectious pathogens to reduce their pathogenicity;

XLI. Claims 138-140, drawn to a method of selectively activating specific regions of selected molecules to increase the production of desired products in a chemical reaction;

XLII. Claims 141 and 142, drawn to a method of selectively activating molecular species or specific regions of molecular species to generate a signal for qualitative or quantitative detection or analysis;

XLIII. Claim 143, drawn to a method for creating sub-picosecond laser pulses;

XLIV. Claim 144, drawn to a method of creating a tightly coherent string of sub-picosecond laser pulses; and

XLV. Claim 145, drawn to a method of creating a structured electromagnetic field.

In response, Applicants elect Group I, claims 1 to 12, drawn to a method of modifying the bioavailability of a bioactive substance.

Applicants submit that the entire application is in condition for allowance, an early notice of which would be appreciated. Should the Examiner not agree with Applicants' position, a personal or telephonic interview is respectfully requested to discuss any remaining issues prior to the issuance of a further Office Action, and to expedite the allowance of the application.

No fee is believed to be due for the filing of this Amendment. Please charge any fees that may be required to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Dated: December 3, 2008

By: Alan P. Force  
Alan P. Force  
Reg. No. 39,673  
One Broadway  
New York, NY 10004  
(212) 425-7200